Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxart Inc (VXRT)

Vaxart Inc (VXRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 87,627
  • Shares Outstanding, K 240,074
  • Annual Sales, $ 28,700 K
  • Annual Income, $ -66,950 K
  • EBIT $ -49 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.88
  • Price/Sales 3.04
  • Price/Cash Flow N/A
  • Price/Book 3.11
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings $-0.04 on 11/13/25
  • Next Earnings Date 03/19/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 67.44%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 35) 0.2380 (65.15%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 0.1273 to 0.6033

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3304 +8.96%
on 11/24/25
0.4200 -14.29%
on 11/14/25
-0.0026 (-0.72%)
since 11/12/25
3-Month
0.3050 +18.03%
on 11/04/25
0.4444 -18.99%
on 11/06/25
-0.0300 (-7.69%)
since 09/12/25
52-Week
0.2606 +38.14%
on 07/09/25
0.9800 -63.27%
on 01/07/25
-0.2365 (-39.65%)
since 12/12/24

Most Recent Stories

More News
Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment...

VXRT : 0.3700 (+1.37%)
Vaxart to Host Upcoming Conference Calls

Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07,...

VXRT : 0.3700 (+1.37%)
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

EMERYVILLE, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines,...

DVAX : 10.80 (-0.55%)
VXRT : 0.3700 (+1.37%)
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing...

DVAX : 10.80 (-0.55%)
VXRT : 0.3700 (+1.37%)
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based...

VXRT : 0.3700 (+1.37%)
Vaxart Secures Funding for COVID-19 Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vaxart (...

VXRT : 0.3700 (+1.37%)
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant...

VXRT : 0.3700 (+1.37%)
Vaxart Appoints W. Mark Watson as Lead Independent Director

In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board’s interests with stockholders Vaxart encourages all stockholders of record on July 29,...

VXRT : 0.3700 (+1.37%)
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH...

VXRT : 0.3700 (+1.37%)
Vaxart Announces Adjournment of Special Meeting of Stockholders

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations...

VXRT : 0.3700 (+1.37%)

Business Summary

Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick...

See More

Key Turning Points

3rd Resistance Point 0.4070
2nd Resistance Point 0.3890
1st Resistance Point 0.3770
Last Price 0.3700
1st Support Level 0.3470
2nd Support Level 0.3290
3rd Support Level 0.3170

See More

52-Week High 0.9800
Fibonacci 61.8% 0.7052
Fibonacci 50% 0.6203
Fibonacci 38.2% 0.5354
Last Price 0.3700
52-Week Low 0.2606

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar